Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22387920 | 1.00 | SIRT2 (0.55) | SIRT2SIRT1SIRT3SIRT5MEN1 | |
| SCHEMBL31559077 | 0.93 | SIRT5 (0.57) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL22387792 | 0.92 | SIRT2 (0.54) | SIRT2SIRT1SIRT3SIRT5MEN1 | |
| SCHEMBL19783968 | 0.92 | SIRT2 (0.53) | SIRT2SIRT1SIRT3SIRT5MEN1 | |
| SCHEMBL25932816 | 0.91 | SIRT5 (0.62) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL30527290 | 0.91 | SIRT5 (0.62) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL31558965 | 0.91 | SIRT2 (0.50) | SIRT2SIRT1SIRT3SIRT5CA2 | |
| SCHEMBL20888703 | 0.89 | SIRT2 (0.51) | SIRT2SIRT1SIRT3SIRT5MEN1 | |
| SCHEMBL31558966 | 0.89 | SIRT5 (0.49) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL18099942 | 0.89 | SIRT2 (0.58) | SIRT2SIRT1SIRT3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648799-A1 | LIGAND-DRUG CONJUGATES | Sun Pharma Advanced Research Company Ltd (IN) | 2025-11-19 | — | — | EP | disclosed |
| US-20250242034-A1 | PHOSPHORAMIDATE-BASED PSMA-TARGETED SMALL-MOLECULE DRUG CONJUGATES | CANCER TARGETED TECH LLC (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4472668-A1 | PHOSPHORAMIDATE-BASED PSMA-TARGETED SMALL-MOLECULE DRUG CONJUGATES | Cancer Targeted Technology LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118804765-A | PSMA targeted small molecule drug conjugate based on phosphoramidate | 癌靶技术有限责任公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024150132-A1 | LIGAND-DRUG CONJUGATES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024150132-A1 | LIGAND-DRUG CONJUGATES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023150543-A1 | PHOSPHORAMIDATE-BASED PSMA-TARGETED SMALL-MOLECULE DRUG CONJUGATES | CANCER TARGETED TECHNOLOGY LLC (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-2021077317-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREFOR | 烟台迈百瑞国际生物医药股份有限公司 | 2021-04-29 | — | — | WO | disclosed |
| US-20200360532-A1 | PROCESS FOR THE PREPARATION OF DRUG LINKER COMPOUNDS | SEAGEN INC. | 2020-11-19 | — | — | US | disclosed |
| EP-2928902-B1 | CONJUGATE COMPOUNDS | VICTORIA LINK LTD (NZ) | 2019-07-17 | — | — | EP | disclosed |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20150352219-A1 | CONJUGATE COMPOUNDS | VICTORIA LINK LIMITED (NZ) | 2015-12-10 | — | — | US | disclosed |
| WO-2015095227-A2 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-7553816-B2 | p-amidobenzylethers in drug delivery agents | SEATTLE GENETICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553816-B2 | p-amidobenzylethers in drug delivery agents | SEATTLE GENETICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | SIRT2 3512/4885SIRT1 2709/4885SIRT3 3528/4885 |
| US-20250242034-A1 | PHOSPHORAMIDATE-BASED PSMA-TARGETED SMALL-MOLECULE DRUG CONJUGATES | FOLH1, KLK3, ACP3 | SIRT2 3610/4885SIRT1 3538/4885SIRT3 3905/4885 |
| US-20150352219-A1 | CONJUGATE COMPOUNDS | SGMS1, SGMS2, ENPP2 | SIRT2 1987/4885SIRT1 2519/4885SIRT3 3126/4885 |
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | SIRT2 3512/4885SIRT1 2709/4885SIRT3 3528/4885 |
| US-20200360532-A1 | PROCESS FOR THE PREPARATION OF DRUG LINKER COMPOUNDS | FPGS, PAICS, DHFR | SIRT2 1629/4885SIRT1 930/4885SIRT3 745/4885 |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | SIRT2 3885/4885SIRT1 3409/4885SIRT3 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.